

Glucagon-like Peptide 1 (GLP-1) Analogues Market - 2024-2033

<https://marketpublishers.com/r/GBF9E0FF1150EN.html>

Date: March 2026

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: GBF9E0FF1150EN

Abstracts

The Glucagon-like Peptide 1 (GLP-1) Analogues Market was valued at US\$ 62.81 Billion in 2024 and is anticipated to reach US\$ 299.08 Billion by 2033, at a CAGR of 0.176 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Glucagon-like Peptide 1 (GLP-1) Analogues Market.

This report delivers a comprehensive overview of the Glucagon-like Peptide 1 (GLP-1) Analogues Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Glucagon-like Peptide 1 (GLP-1) Analogues Market. The Glucagon-like Peptide 1 (GLP-1) Analogues Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Glucagon-like Peptide 1 (GLP-1) Analogues Market Scope:

Key Players

Eli Lilly and Company

Major Highlights

This report delivers a comprehensive overview of the Glucagon-like Peptide 1 (GLP-1) Analogues Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Glucagon-like Peptide 1 (GLP-1) Analogues Market. The Glucagon-like Peptide 1 (GLP-1) Analogues Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned

to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Product
- 2.4. Snippet by Type
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by Application
- 2.7. Snippet by Distribution Channel
- 2.8. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Increasing Prevalence of Obesity and Type 2 Diabetes
 - 3.1.1.2. Clinical Efficacy and Safety
 - 3.1.1.3. Product Innovation and Strong Pipeline
 - 3.1.2. Restraints
 - 3.1.2.1. High Cost of Medications
 - 3.1.2.2. Competition from Alternative Therapies
 - 3.1.2.3. Regulatory and Reimbursement Challenges
 - 3.1.3. Opportunity
 - 3.1.3.1. Expansion into New Therapeutic Areas
 - 3.1.3.2. Innovative Drug Combinations
- 3.2. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players

- 4.1.2. Established leaders with the largest-selling Brand
- 4.1.3. Market leaders with established Product
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. South America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.11. Pricing Analysis and Price Dynamics

5. GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ANALOGUES MARKET, BY PRODUCT

- 5.1. Introduction
 - 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
 - 5.1.2. Market Attractiveness Index, By Product
- 5.2. Ozempic*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Trulicity
- 5.4. Mounjaro
- 5.5. Wegovy
- 5.6. Rybelsus
- 5.7. Saxenda
- 5.8. Victoza
- 5.9. Zepbound
- 5.10. Others

6. GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ANALOGUES MARKET, BY TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

6.1.2. Market Attractiveness Index, By Type

6.2. Long-acting GLP-1 Agonist*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Short-acting GLP-1 Agonist

7. GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

7.1.2. Market Attractiveness Index, By Route of Administration

7.2. Subcutaneous*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Oral

8. GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ANALOGUES MARKET, BY APPLICATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.1.2. Market Attractiveness Index, By Application

8.2. Type 2 Diabetes Mellitus*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Obesity

8.4. Others

9. GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ANALOGUES MARKET, BY DISTRIBUTION CHANNEL

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.1.2. Market Attractiveness Index, By Distribution Channel

9.2. Hospital Pharmacies*

- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies

10. GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1) ANALOGUES MARKET, BY REGION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
 - 10.2.1. Introduction
 - 10.2.2. Key Region-Specific Dynamics
 - 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
 - 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.2.8.1. U.S.
 - 10.2.8.2. Canada
 - 10.2.8.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics
 - 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
 - 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.3.8.1. Germany
 - 10.3.8.2. U.K.
 - 10.3.8.3. France
 - 10.3.8.4. Spain
 - 10.3.8.5. Italy

10.3.8.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.8.1. Brazil

10.4.8.2. Argentina

10.4.8.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.8.1. China

10.5.8.2. India

10.5.8.3. Japan

10.5.8.4. South Korea

10.5.8.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

- 11.1. Competitive Overview and Key Market Players
- 11.2. Market Share Analysis and Positioning Matrix
- 11.3. Strategic Partnerships, Mergers & Acquisitions
- 11.4. Key Developments in Product Portfolios and Innovations
- 11.5. Company Benchmarking

12. COMPANY PROFILES

- 12.1. Eli Lilly and Company*
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio
 - 12.1.2.1. Product Description
 - 12.1.2.2. Product Key Performance Indicators (KPIs)
 - 12.1.2.3. Historic and Forecasted Product Sales
 - 12.1.2.4. Product Sales Volume

13. FINANCIAL OVERVIEW

- 13.1. Company Revenue
 - 13.1.1. Geographical Revenue Shares
 - 13.1.1.1. Revenue Forecasts
 - 13.1.2. Key Developments
 - 13.1.2.1. Mergers & Acquisitions
 - 13.1.2.2. Key Product Development Activities
 - 13.1.2.3. Regulatory Approvals, etc.
 - 13.1.3. SWOT Analysis

14. NOVO NORDISK A/S.

- 14.1. Sanofi
- 14.2. AstraZeneca
- 14.3. Boehringer Ingelheim, Inc.
- 14.4. Glenmark Pharmaceuticals Ltd.
- 14.5. Hanmi Pharm.Co., Ltd.
- 14.6. Amgen Inc.
- 14.7. Gmax Biopharm.
- 14.8. Sciwind Biosciences Co., Ltd. (*LIST NOT EXHAUSTIVE)

15. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 15.1. Data Collection Methods
- 15.2. Data Triangulation
- 15.3. Forecasting Techniques
- 15.4. Data Verification and Validation

16. APPENDIX

- 16.1. About Us and Services
- 16.2. Contact Us

I would like to order

Product name: Glucagon-like Peptide 1 (GLP-1) Analogues Market - 2024-2033

Product link: <https://marketpublishers.com/r/GBF9E0FF1150EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBF9E0FF1150EN.html>